A method of performing antimicrobial susceptibility testing (AST) on a sample uses a reader device that mounts on a mobile phone having a camera. A microtiter plate containing wells preloaded with the bacteria-containing sample, growth medium, and drugs of differing concentrations is loaded into the reader device. The wells are illuminated using an array of illumination sources contained in the reader device. Images of the wells are acquired with the camera of the mobile phone. In one embodiment, the images are transmitted to a separate computing device for processing to classify each well as turbid or not turbid and generating MIC values and a susceptibility characterization for each drug in the panel based on the turbidity classification of the array of wells. The MIC values and the susceptibility characterizations for each drug are transmitted or returned to the mobile phone for display thereon.

A microorganism test method includes: covering, with a hydrophobic capping solvent, a sample containing a specimen and a liquid culture medium, within a region in a vicinity of a sensor configured to detect a microorganism contained in the specimen; and calculating, based on an output from the sensor, information indicating a degree of growth of the microorganism contained in the specimen. For example, an analysis unit drives an array sensor in which many resonators are arranged in a matrix pattern, stores a resonance frequency of a resonator which is acquired at the time of starting the measurement as an initial frequency, and calculates a difference (frequency shift) between the initial frequency and a resonance frequency of the resonator which is measured at predetermined time intervals as information indicating a degree of growth of the microorganism contained in the specimen.

The disclosure is directed at a system and method for non-microbial prediction of antimicrobial efficacy of an antimicrobial item, such as, a metal surface or materials impregnated with biocidal metal ions or nanoparticles. A test formulation is applied to a surface of interest and a color change of the test formulation is then analyzed and then correlated with antimicrobial activity.

The disclosure is directed at a system and method for non-microbial prediction of antimicrobial efficacy of an antimicrobial item, such as, a metal surface or materials impregnated with biocidal metal ions or nanoparticles. A test formulation is applied to a surface of interest and a color change of the test formulation is then analyzed and then correlated with antimicrobial activity.

Disclosed herein is a rapid genetics-free method for eliciting and detecting cryptic metabolites using an imaging mass spectrometry-based approach. An organism of choice is challenged with elicitors from a small molecule library. The molecules elicited are then imaged by mass spec, which allows for rapid identification of cryptic metabolites. These are then isolated and characterized. Employing the disclosed approach activated production of cryptic glycopeptides from an actinomycete bacterium. The molecules that result, the keratinimicins and keratinicyclins, are metabolites with important structural features. At least two of these, keratinimicins B and C, are highly bioactive against several pathogenic strains. This approach will allow for rapid activation and identification of cryptic metabolites from diverse microorganisms in the future.

Disclosed herein is a rapid genetics-free method for eliciting and detecting cryptic metabolites using an imaging mass spectrometry-based approach. An organism of choice is challenged with elicitors from a small molecule library. The molecules elicited are then imaged by mass spec, which allows for rapid identification of cryptic metabolites. These are then isolated and characterized. Employing the disclosed approach activated production of cryptic glycopeptides from an actinomycete bacterium. The molecules that result, the keratinimicins and keratinicyclins, are metabolites with important structural features. At least two of these, keratinimicins B and C, are highly bioactive against several pathogenic strains. This approach will allow for rapid activation and identification of cryptic metabolites from diverse microorganisms in the future.

The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Staphylococcus aureus strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy and as companion diagnostic.

The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Staphylococcus aureus strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy and as companion diagnostic.

Disclosed herein are methods and devices for rapid assessment of whether a microorganism present in a sample is susceptible or resistant to a treatment.

Disclosed herein are methods and devices for rapid assessment of whether a microorganism present in a sample is susceptible or resistant to a treatment.